Type of parameter | Base Case value | References |
---|---|---|
Demographics | ||
Population | 60,795,612 | [18] |
Male in the health plan (% of total) | 48.5% | [17] |
Paediatric in the health plan (% of total) | 11.9% | [17] |
Annual population growth | 0.5% | [18] |
Paediatric weight (Kg) | 18.5 | [21] |
Adult weight (Kg) | 70.6 | [22] |
Epidemiology | ||
HA prevalence in male | 12.7 per 100,000 | [16] |
Severity distribution of the disease | ||
Mild | 39.7% | [16] |
Moderate | 14.1% | |
Severe | 46.2% | |
Patients without inhibitors | ||
Mild | 99.1% | [16] |
Moderate | 96.3% | |
Severe | 81.6% | |
Treatment regimen among adults | ||
On demand | 42.8% | [16] |
Prophylaxis | 55.2% | |
Treatment regimen among paediatrics | ||
On demand | 0% | Assumption based on the opinion of clinical experts |
Prophylaxis | 100% | |
Costs | ||
rFVIIIFc unit cost (€/IU) | 0.72 | [25] |
Advate® unit cost (€/IU) | 0.65 | [25] |
Kogenate® unit cost (€/IU) | 0.69 | [25] |
Refacto® unit cost (€/IU) | 0.69 | [25] |
Helixate® unit cost (€/IU) | 0.69 | [25] |
Recombinate® unit cost (€/IU) | 0.60 | [25] |
Plasma-derived unit cost (€/IU) | 0.60 | [25] |